A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study (Q33452892)

26 July 2017

title

A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study (English)

1 reference

26 July 2017

1 reference

James M Prosser

1

1 reference

26 July 2017

Samantha Yard

2

1 reference

26 July 2017

Annie Steele

3

1 reference

26 July 2017

Lisa J Cohen

4

1 reference

26 July 2017

Igor I Galynker

5

1 reference

26 July 2017

publication date

26 May 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

9

1 reference

26 July 2017

page(s)

25

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-244x-9-25

26 July 2017

exact match

0 references

cites work

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Panic attacks, panic disorder, and agoraphobia: associations with substance use, abuse, and dependence

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

An open-label trial of risperidone augmentation for refractory anxiety disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Serotonin function in panic disorder: important, but why?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

The epidemiology of panic disorder and agoraphobia in Europe

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Management of panic disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Evidence-based pharmacotherapy of panic disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Mesolimbic dopaminergic pathways in fear conditioning

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Overview of panic and social anxiety disorders.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Treatment-resistant panic disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Three year naturalistic outcome study of panic disorder patients treated with paroxetine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

WCA recommendations for the long-term treatment of panic disorder.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

A rating scale for depression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

The assessment of anxiety states by rating

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Reliability and validity of the Panic Disorder Severity Scale: replication and extension

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Comorbidity of mood and anxiety disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Lifetime panic-depression comorbidity in the National Comorbidity Survey

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

The impact of comorbidity on the treatment of panic disorder.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Evidence that conditioned stress enhances outflow of dopamine in rat prefrontal cortex: a search for the influence of diazepam and 5-HT1A agonists.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Effect of conditioned fear stress on dopamine release in the rat prefrontal cortex.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

The relationship between panic disorder and major depression. A new family study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Comorbidity of panic and major depressive disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Survey on the pharmacodynamics of the new antipsychotic risperidone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Development of a Rating Scale for Primary Depressive Illness

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Missing data in longitudinal studies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Medical evaluation of panic attacks.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Reduced serotonin type 1A receptor binding in panic disorder.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Current Comorbidity of Psychiatric Disorders Among DSM-IV Major Depressive Disorder Patients in Psychiatric Care in the Vantaa Depression Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

The effect of diagnostic hierarchy in genetic epidemiological studies of psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Dimensional structure of the Hamilton Depression Rating Scale in patients with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

l-Sulpiride, at a low, non-neuroleptic dose, prevents conditioned fear stress-induced freezing behavior in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Adherence with referrals for outpatient follow-up from a VA psychiatric emergency room.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-9-25

Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

The pharmacotherapy of panic disorder.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

Risperidone for resistant anxiety in elderly persons

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2696444

A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants

31 October 2018

1 reference

12 December 2020

Atypical antipsychotics for treatment of mixed depression and anxiety

1 reference

12 December 2020

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder

1 reference

12 December 2020

A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES

1 reference

12 December 2020

Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors

1 reference

12 December 2020

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

12 December 2020

The issue of comorbidity in the treatment of panic

1 reference

12 December 2020

Effects of risperidone on affective symptoms in patients with schizophrenia

1 reference

12 December 2020

Panic disorder: long-term pharmacotherapy and discontinuation

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-244X-9-25

1 reference

Dimensions Publication ID

26 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-244x-9-25

9 September 2019

1 reference

26 July 2017

1 reference